Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis
Heliyon, 2023 Introduction: Azivudine has undergone a few randomized controlled trials (RCTs) as of late. This study aimed to assess the COVID-19 treatment with azvudine's efficacy and safety.
Zhaoyan Chen, Fangyuan Tian
exaly +5 more sources
Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study [PDF]
BMC Infectious DiseasesBackground Patients with kidney disease (KD) are at high risk of contracting COVID-19 and developing severe disease. There is still a lack of guidance regarding the treatment of COVID-19 in patients with KD.
Benchen Rao +14 more
doaj +3 more sources
ViewKidney disease has been the main risk factor of poor prognosis for COVID‐19 patients. The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease have not been reported. Herein, we conducted a nine‐center and retrospective
Bo Yu +13 more
doaj +3 more sources
Virology JournalBackground Azvudine has been approved for the treatment of coronavirus disease 2019 (COVID-19) patients in China, and this meta-analysis aims to illustrate the safety of azvudine and its effectiveness in reducing mortality. Methods PubMed, Embase, Web of
Yaqi Wang +12 more
doaj +4 more sources
A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years [PDF]
Acta Pharmaceutica Sinica BAzvudine and nirmatrelvir/ritonavir (Paxlovid) are recommended for COVID-19 treatment in China, but their safety and efficacy in the elderly population are not fully known.
Bo Yu +17 more
doaj +3 more sources
Scientific ReportsThis study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate COVID-19.
Zhi-Guo Zhou
exaly +3 more sources
Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China [PDF]
Frontiers in PharmacologyIntroduction: Numerous studies have explored the treatment outcomes of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19. However, direct comparisons between these two drugs are still relatively limited.
Nan Shang +4 more
doaj +4 more sources
Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study [PDF]
Frontiers in Cellular and Infection MicrobiologyBackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further research ...
Yingkai Xu +7 more
doaj +4 more sources
Journal of Infection and Public HealthBackground: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally.
Wei Yang +6 more
doaj +4 more sources
PLoS ONE, 2014 Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or
Rui-Rui Wang +11 more
doaj +2 more sources